Mercer Global Advisors
VKTX icon

Mercer Global Advisors’s Viking Therapeutics VKTX Stock Holding History

Mercer Global Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$442K Buy
11,326
+1,267
+13% +$40.9K ﹤0.01% 2407
2026
Q1 		$327K Buy
10,059
+3,373
+50% +$108K ﹤0.01% 2349
2025
Q4 		$235K Buy
+6,686
New +$237K ﹤0.01% 2433
2020
Q2 		– Sell
-10,640
Closed -$50K – 1180
2020
Q1 		$50K Sell
10,640
-740
-7% -$4.55K ﹤0.01% 1051
2019
Q4 		$91K Buy
+11,380
New +$83K ﹤0.01% 1126

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Mercer Global Advisors's VKTX Position: Q2 2026 in Review

Mercer Global Advisors increased its Viking Therapeutics (VKTX) stake by 13% in Q2 2026, buying an estimated $40.9K and bringing the position to 11,326 shares worth $442K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.

Mercer Global Advisors first reported a position in VKTX in Q4 2019 and has held it in 5 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Mercer Global Advisors held 11,326 shares of Viking Therapeutics worth $442K as of Q2 2026.
  • Mercer Global Advisors bought 1,267 Viking Therapeutics shares in Q2 2026, an estimated $40.9K.
  • Viking Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2407 holding.
  • Mercer Global Advisors first reported a position in Viking Therapeutics in Q4 2019 and has held it in 5 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.